INTS6L

Across TCGA pan-cancer cohorts, INTS6L mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated INTS6L data layer compared with 24 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher INTS6L mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated INTS6L expression acts as an unfavorable survival marker, although some lineages such as HNSC show a favorable association.

HNSC, LSCC, and LUAD are the cancer types where INTS6L mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	DFS	Median	All	1.000	0.678	.016	23	view →
LSCC	OS	Median	II,III,IV	0.876	1.000	.035	3	view →
LUAD	OS	Median	All	0.923	1.000	.037	1	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

INTS6L–HNSC (DFS)

Open the HNSC breakdown →